My ePortfolio Register   
 

Abstract | Full HTML Article | PDF | Portuguese ecancer 11 765 / DOI: 10.3332/ecancer.2017.765

Short Communication

The cost of cancer treatment in Portugal

Introduction: Cancer is the second most common cause of death in Portugal, with 24.3% of these deaths caused by malignant neoplasms. The strong impact on lost productivity and rising treatment costs make cancer a priority. In order to understand, compare, and control costs by promoting transparency in the health system, it is vital to analyse the cost of oncological diseases. This study aims to estimate the economic burden associated with the treatment of cancer in Portugal by calculating the direct medical costs.

Materials and methods: A prevalence-based study was conducted. The approachs used to estimate the costs were the top-down and gross costing techniques. In order to identify, quantify, and value all of the costs associated with the treatment of cancer, several sources of data were consulted to obtain the most up-to-date information on hospital care and a modified Delphi Panel was created to obtain data on primary health care.

Results: The annual cost of cancer treatment in Portugal amounted to 867 million euros, representing 5.5% of the total expenditure for health and 84 euros per capita. The main component of this cost is antineoplastic drugs, which account for 31.5% of the total.

Discussion and conclusion: By comparing the costs calculated in this study with those of the single Portuguese study conducted in 2009 and the European study carried out in 2013, we found that the annual cost for cancer treatment increased by about 300 million euros. An increase in incidence and the rising cost of drugs can explain this difference.

Keywords: cancer, health, economics, costs, health technology assessment

Categories:

Economics

Loading Article Metrics ... Please wait

Related articles

Conference Report: Highlights from the 15th St Gallen International Breast Cancer Conference 15–18 March, 2017, Vienna: tailored treatments for patients with early breast cancer

Abstract | Full Article | PDF Published: 07 Apr 2017 / DOI: 10.3332/ecancer.2017.732

Policy: Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group

Abstract | Full Article | PDF | Portuguese | Spanish Published: 26 Jan 2017 / DOI: 10.3332/ecancer.2017.716

Special Issue: The cost of cancer care is not related to its outcomes

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.687

Special Issue: Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.686

Special Issue: Health technology assessment and value: the cancer value label (CAVALA) methodology

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.685



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence